https://observatorio.fm.usp.br/handle/OPI/47256
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | LAGE, Luis Alberto de Padua Covas | - |
dc.contributor.author | BRITO, Claudio Vinicius | - |
dc.contributor.author | LEVY, Debora | - |
dc.contributor.author | CULLER, Hebert Fabricio | - |
dc.contributor.author | COUTO, Samuel Campanelli Freitas | - |
dc.contributor.author | OLIVEIRA, Lucas Bassolli Alves de | - |
dc.contributor.author | ZERBINI, Maria Claudia Nogueira | - |
dc.contributor.author | ROCHA, Vanderson | - |
dc.contributor.author | PEREIRA, Juliana | - |
dc.date.accessioned | 2022-06-20T15:32:05Z | - |
dc.date.available | 2022-06-20T15:32:05Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | LEUKEMIA RESEARCH, v.114, article ID 106794, 9p, 2022 | - |
dc.identifier.issn | 0145-2126 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/47256 | - |
dc.description.abstract | Background: Nodal peripheral T-cell lymphomas (nPTCL) encompass a heterogeneous group of mature and aggressive lymphoid malignancies, including peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), angioimmunoblastic T-cell lymphoma (AITL) and anaplastic large cell lymphoma (ALCL) ALK-positive and ALKnegative. Their differential diagnosis and prognosis are an issue in clinical practice. Accurate biomarkers to define the different subtypes of nPTCL and to stratify their prognosis are essential to improve their treatment approach. The aim of this study was to test the prognostic impact of GATA-3 gene expression, and its capability to discriminate the different subtypes of nPTCL. Patients and methods: We retrospectively assessed GATA-3 gene expression by quantitative real time PCR (qRTPCR) from neoplastic biopsies in Formalin-Fixed Paraffin-Embedded samples (FFPE) of 80 patients with nPTCL that were admitted in a single cancer treatment center from 2000 to 2017. Results: Median age was 49 years-old (IqR 34-59), 43/80 (53.7%) were male. Median follow-up was 1.72 years, 36.3% were classified as PTCL, NOS, 31.2% as ALK-negative ALCL, 21.2% as ALK-positive ALCL and 11.3% as AITL. The majority of cases had advanced stage cancer (III/IV). Two-year estimated overall survival (OS) and progression-free survival (PFS) were 52.2% and 39.5%, respectively. The median GATA-3 gene expression level | eng |
dc.description.sponsorship | FAPESP [2012/50495-3] | - |
dc.language.iso | eng | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | eng |
dc.relation.ispartof | Leukemia Research | - |
dc.rights | restrictedAccess | eng |
dc.subject | Nodal peripheral T-cell lymphomas | eng |
dc.subject | Angioimmunoblastic T-cell lymphoma (AITL) | eng |
dc.subject | Diagnosis | eng |
dc.subject | Prognosis | eng |
dc.subject | GATA-3 gene expression | eng |
dc.subject | Peripheral T-cell lymphoma | eng |
dc.subject | not otherwise specified (PTCL | eng |
dc.subject | NOS) | eng |
dc.subject | ALK-negative anaplastic large-cell lymphoma (ALK-negative ALCL) | eng |
dc.subject.other | gata-3 | eng |
dc.subject.other | disease | eng |
dc.subject.other | marker | eng |
dc.subject.other | adults | eng |
dc.title | Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort | eng |
dc.type | article | eng |
dc.rights.holder | Copyright PERGAMON-ELSEVIER SCIENCE LTD | eng |
dc.identifier.doi | 10.1016/j.leukres.2022.106794 | - |
dc.identifier.pmid | 35131666 | - |
dc.subject.wos | Peripheral Vascular Disease | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | BRITO, Claudio Vinicius:Sao Paulo Univ FMUSP, Fac Med, Dept Hematol Hemotherapy & Cell Therapy, Sao Paulo, Brazil | - |
hcfmusp.description.articlenumber | 106794 | - |
hcfmusp.description.volume | 114 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000788077600008 | - |
hcfmusp.origem.id | 2-s2.0-85123988600 | - |
hcfmusp.publisher.city | OXFORD | eng |
hcfmusp.publisher.country | ENGLAND | eng |
hcfmusp.relation.reference | Agarwal H, 2019, INDIAN J PATHOL MICR, V62, P244, DOI 10.4103/IJPM.IJPM_228_18 | eng |
hcfmusp.relation.reference | Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050 | eng |
hcfmusp.relation.reference | Castellar ERP, 2014, BLOOD, V124, P1473, DOI 10.1182/blood-2014-04-571091 | eng |
hcfmusp.relation.reference | Cheng Y, 2009, INT IMMUNOPHARMACOL, V9, P894, DOI 10.1016/j.intimp.2009.03.014 | eng |
hcfmusp.relation.reference | Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800 | eng |
hcfmusp.relation.reference | d'Amore F, 2012, J CLIN ONCOL, V30, P3093, DOI 10.1200/JCO.2011.40.2719 | eng |
hcfmusp.relation.reference | Davis DG, 2016, HUM PATHOL, V47, P26, DOI 10.1016/j.humpath.2015.09.015 | eng |
hcfmusp.relation.reference | de Padua Covas Lage Luis Alberto, 2019, Oncotarget, V10, P5136, DOI 10.18632/oncotarget.27098 | eng |
hcfmusp.relation.reference | Dorfman DM, 2017, HUM PATHOL, V65, P166, DOI 10.1016/j.humpath.2017.05.009 | eng |
hcfmusp.relation.reference | Falini B, 1999, BLOOD, V93, P2697 | eng |
hcfmusp.relation.reference | Frelin C, 2013, NAT IMMUNOL, V14, P1037, DOI 10.1038/ni.2692 | eng |
hcfmusp.relation.reference | Heavican TB, 2019, BLOOD, V133, P1664, DOI 10.1182/blood-2018-09-872549 | eng |
hcfmusp.relation.reference | Iqbal J, 2014, BLOOD, V123, P2915, DOI 10.1182/blood-2013-11-536359 | eng |
hcfmusp.relation.reference | Kansara R, 2014, LEUKEMIA LYMPHOMA, V55, P727, DOI 10.3109/10428194.2013.858154 | eng |
hcfmusp.relation.reference | Lage Luis Alberto de Pádua Covas, 2015, Rev. Bras. Hematol. Hemoter., V37, P277, DOI 10.1016/j.bjhh.2015.03.017 | eng |
hcfmusp.relation.reference | Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262 | eng |
hcfmusp.relation.reference | Ma H, 2017, INT J CLIN ONCOL, V22, P18, DOI 10.1007/s10147-016-1045-2 | eng |
hcfmusp.relation.reference | Mete O, 2019, MODERN PATHOL, V32, P484, DOI 10.1038/s41379-018-0167-7 | eng |
hcfmusp.relation.reference | Ortiz-Rey JA, 2017, ACTAS UROL ESP, V41, P577, DOI 10.1016/j.acuro.2017.03.004 | eng |
hcfmusp.relation.reference | Perez-Andreu V, 2013, NAT GENET, V45, P1494, DOI 10.1038/ng.2803 | eng |
hcfmusp.relation.reference | Petrich AM, 2015, BRIT J HAEMATOL, V168, P708, DOI 10.1111/bjh.13202 | eng |
hcfmusp.relation.reference | Pro B, 2017, BLOOD, V130, P2709, DOI 10.1182/blood-2017-05-780049 | eng |
hcfmusp.relation.reference | Ronaghy A, 2018, INT J GYNECOL PATHOL, V37, P284, DOI 10.1097/PGP.0000000000000403 | eng |
hcfmusp.relation.reference | Sachsida-Colombo Elisabetta, 2016, Rev. Bras. Hematol. Hemoter., V38, P82, DOI 10.1016/j.bjhh.2015.11.002 | eng |
hcfmusp.relation.reference | Sibon D, 2019, HAEMATOLOGICA, V104, pE562, DOI 10.3324/haematol.2018.213512 | eng |
hcfmusp.relation.reference | Sibon D, 2012, J CLIN ONCOL, V30, P3939, DOI 10.1200/JCO.2012.42.2345 | eng |
hcfmusp.relation.reference | Suzuki R, 2000, BLOOD, V96, P2993 | eng |
hcfmusp.relation.reference | Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569 | eng |
hcfmusp.relation.reference | Tozbikian GH, 2019, HUM PATHOL, V85, P221, DOI 10.1016/j.humpath.2018.11.005 | eng |
hcfmusp.relation.reference | Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558 | eng |
hcfmusp.relation.reference | Wang YQ, 2013, NAT IMMUNOL, V14, P714, DOI 10.1038/ni.2623 | eng |
hcfmusp.relation.reference | Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y | eng |
hcfmusp.relation.reference | Zhang W, 2016, ONCOTARGET, V7, P65284, DOI 10.18632/oncotarget.11673 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1873-5835 | - |
hcfmusp.citation.scopus | 3 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - FM/MPT Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - LIM/14 Artigos e Materiais de Revistas Científicas - LIM/19 Artigos e Materiais de Revistas Científicas - LIM/31 Artigos e Materiais de Revistas Científicas - ODS/03 Artigos e Materiais de Revistas Científicas - ODS/10 |
File | Description | Size | Format | |
---|---|---|---|---|
art_LAGE_Diagnostic_and_prognostic_implications_of_tumor_expression_of_2022.PDF Restricted Access | publishedVersion (English) | 1.17 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.